NICE Issues Guidance for Flu for NHS Patients in England and Wales
of Leicester researchers among medical scientists conducting investigation
its latest guidance documents on the use of ostletamivir and zanamivir for the
treatment of 'flu the
National Institute for Clinical Excellence (NICE or 'the Institute') has
That, where it is known that either influenza A or influenza B is
circulating in the community, zanamivir and oseltamivir are recommended for the
treatment of at-risk adults and children who present with influenza-like illness
(ILI) and who can start therapy within 48 hours of the onset of symptoms.
Amantadine is not recommended for the treatment of influenza.
Dillon, Chief Executive, commented on the flu drugs appraisal: “This guidance
further increases the options available to health professionals when treating
people who are considered to be 'at risk' when they develop 'flu. The message,
though, for most people, who are not in one of the at risk categories, in
treating flu remains the same: use over-the-counter medicines to treat the
multi-disciplinary research team comprised David Turner, Dr Nicola Cooper, Dr
Alex Sutton and Professor Keith Abrams of the Department of Epidemiology &
Public Health at the University of Leicester and Professor Karl Nicholson,
Department of Microbiology & Immunology, University of Leicester and Allan
Wailoo, Health Economics Group, School of Health & Related Research,
University of Sheffield.
Abrams said: “Reviewing the worldwide evidence and developing a sophisticated
mathematical model for such a complex, but common, disease as 'flu has taken us
over 18 months, but it is already helping to inform NHS policy and future
TO NEWSDESK: For
more information, please contact: Professor Keith R. Abrams,
This document has been approved by the head of department or section.